Clinical Data GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail BioSpaceCamlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, "is unlikely to transform patient care," the pharma said.RespiratoryRead full story pharminent July 17, 2026 (Last updated: July 20, 2026) BioSpace Camlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said. Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Merck Wins First FDA Approval of an Oral PCSK9 Inhibitor with Cholesterol Pill LipfendraNext: Novo Lands European Oral Wegovy Approval Before Lilly Can Respond Related Stories Clinical Data AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug pharminent July 15, 2026 Clinical Data AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance pharminent July 15, 2026 Clinical Data Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs pharminent July 14, 2026
